Common stock, $0.01 par value
- Symbol
- DHR
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Danaher Corporation
DHRNYSEEQUITYCurrent
Results of Operations and Financial Condition
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION On July 21, 2026, Danaher Corporation (“Danaher”) issued a press release announcing financial results for the quarter ended June 26, 2026. A copy of the release is furnished herewith as Exhibit 99.1 and incorporated by reference herein.…
Press release in this filing
Innovation at the speed of life Danaher Reports Second Quarter 2026 Results →Company context
Danaher is a leading global life sciences and diagnostics innovator, committed to advancing the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges - accelerating the moment scientific discovery becomes human impact. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. That’s innovation at the speed of life. Explore more at www.danaher.com.
Current securities
Registered securities in this filing
DANAHER CORPORATION · 8-K · Filed 2026-07-21
2.100% Senior Notes due 2026
- Symbol
- DHR 26
- Exchange
- NYSE
- Classification
- DEBT
1.200% Senior Notes due 2027
- Symbol
- DHR/27
- Exchange
- NYSE
- Classification
- DEBT
0.450% Senior Notes due 2028
- Symbol
- DHR/28
- Exchange
- NYSE
- Classification
- DEBT
Floating Rate Senior Notes due 2028
- Symbol
- DHR 28
- Exchange
- NYSE
- Classification
- DEBT
2.500% Senior Notes due 2030
- Symbol
- DHR 30
- Exchange
- NYSE
- Classification
- DEBT
3.250% Senior Notes due 2030
- Symbol
- DHR 30A
- Exchange
- NYSE
- Classification
- DEBT
0.750% Senior Notes due 2031
- Symbol
- DHR/31
- Exchange
- NYSE
- Classification
- DEBT
3.625% Senior Notes due 2034
- Symbol
- DHR 34
- Exchange
- NYSE
- Classification
- DEBT
4.000% Senior Notes due 2038
- Symbol
- DHR 38
- Exchange
- NYSE
- Classification
- DEBT
1.350% Senior Notes due 2039
- Symbol
- DHR/39
- Exchange
- NYSE
- Classification
- DEBT
1.800% Senior Notes due 2049
- Symbol
- DHR/49
- Exchange
- NYSE
- Classification
- DEBT
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On July 21, 2026, Danaher Corporation (“Danaher”) issued a press release announcing financial results for the quarter ended June 26, 2026. A copy of the release is furnished herewith as Exhibit 99.1 and incorporated by reference herein. This Current Report on Form 8-K and the press release attached hereto are being furnished by Danaher pursuant to Item 2.02 of Form 8-K.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Filed exhibits (1)
EX-99.1 2 dhr-20260721xex991.htm EX-99.1 Document Exhibit 99.1 Innovation at the speed of life Danaher Reports Second Quarter 2026 Results WASHINGTON D.C., July 21, 2026 -- Danaher Corporation (NYSE: DHR) today announced results for the second quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted. Key Second Quarter 2026 Results • Net earnings were $870 million, or $1.23 per diluted common share, up 60% year-over-year. • Non-GAAP adjusted diluted net earnings per common share grew 8.0% to $1.94. • Revenues increased 5.5% year-over-year to $6.3 billion. • Non-GAAP core revenue increased 3.0% year-over-year and non-GAAP core revenue excluding respiratory testing revenue increased 4.5% year-over-year. • Operating cash flow was $1.5 billion and non-GAAP free cash flow was $1.3 billion. • Strong Q2 earnings performance and earlier-than-anticipated completion of Masimo acquisition enabling increased full year 2026 adjusted diluted net earnings per common share guidance. Rainer M. Blair, President and Chief Executive Officer, stated, “We delivered a better than expected second…
Open exhibit ↗